Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+therapeutic+antibodies

9 Results

Sort By:

Value Proposition· Target associated with viral load reduction identified from a large pool of study participants who had low level viremia· Potential to reduce disease severity in at-risk populations· Proactive approach to lower viral load in individuals who could become infected Unmet NeedHuman immunodeficiency virus (HIV) impacts millions...

Published: 10/24/2025 | Inventor(s): Susan Eshleman, Harry Larman, Kai Kammers, Oliver Laeyendecker, Wendy Grant-McAuley

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases > HIV, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Polymers for Binding-Triggered Antibody Precipitation and Purification

Value PropositionResults in >97% precipitation yield, >88% elution yield of mAbsSimplified molecular design compared to elastin-like polypeptide (ELP)-based materialsDoes not need additional salt to achieve mAb precipitation and recoveryTechnology DescriptionResearchers at Johns Hopkins have developed a peptide-based platform technology using...

Published: 10/24/2025 | Inventor(s): Honggang Cui, Yi Li, David Stern, XuanKuo Xu, Lye Lin Lock, Jason Mills, Sanchayita Ghose, Zheng Jian Li

Keywords(s):

Category(s): Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Research Tools, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Research Tools > Research Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Disulfide Bond-free and Fibril-specific Nanobodies Prevent the Prion-like α-synuclein Spreading

Unmet NeedLewy bodies dementia (LBD) is one of the most common causes of dementia, including Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB). Both clinical and experimental observations support the hypothesis of prion-like α-syn driving α-synucleinopathy, hence targeting the prion-like α-syn may be a new approach to treat...

Published: 10/24/2025 | Inventor(s): Xiaobo Mao, Wenjing Wang, Yemima Raini, Yuqing Liu, Ramhari Kumbhar

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Dementia, Clinical and Disease Specializations > Neurology > Parkinson’s Disease

Antibody for DNA Degradation

Value Proposition· Autoantibody that promotes DNA degradation to diminish inflammation· Enhances endonuclease DNase1L3 activity· Avoids kidney-mediated inflammatory response Unmet Need· Extracellular DNA, also called cell-free DNA, released from dying cells or activated immune cells can be recognized by the immune system...

Published: 10/24/2025 | Inventor(s): Felipe Andrade, Jose de Jesus Eduardo Gomez-Bañuelos

Keywords(s):

Category(s): Clinical and Disease Specializations > Genetic Diseases > Cystic Fibrosis, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies, Clinical and Disease Specializations > Inflammation > Arthritis

Antibodies Against CCAR1 Confer Protection Against Cancer

Brief DescriptionStanford and JHU researchers identify an autoantibody response in dermatomyositis patients that is protective of cancer, which may have applications in cancer screening and treatment.Technology Summary Researchers at Stanford University and Johns Hopkins University have identified an antibody that is negatively associated with cancer...

Published: 10/24/2025 | Inventor(s): Antony Rosen, Livia Casciola-Rosen, David Fiorentino

Keywords(s):

Highly Specific Monoclonal Antibodies used as Allosteric Inhibitors and Specific Biosensors of Human ZnT8

Unmet NeedType 2 diabetes (T2D) is a growing worldwide public health issue affecting over 500 million people while creating a $1 trillion economic burden on global healthcare economies. Many current and new therapeutics demonstrate varying degrees of effectiveness, but no single agent or combination thereof has been able to provide patients with lasting...

Published: 10/24/2025 | Inventor(s): Dax Fu, Chengfeng Merriman

Keywords(s): Antibodies, Biologics, Diabetes, Discovery/Research Tools, Disease Indication, Metabolic Disorders, Monoclonal Antibodies, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker, Type II Diabetes

Category(s): Technology Classifications > Research Tools > Research Antibodies, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Neuritin Impact T Cell Tolerance Induction and Maintenance and is a Target for Tumor Immunotherapy

Unmet NeedCancer immunotherapy is a therapeutic approach that has revolutionized advanced cancer treatment. In particular, the use of therapeutic blocking antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein (PD-1) has achieved routine clinical use in numerous indications. Despite these promising results, monotherapy...

Published: 10/24/2025 | Inventor(s): Drew Pardoll, Hong Yu, Joseph Barbi, Fan Pan, Charles Drake

Keywords(s): Antibodies, Autoimmune Diseases, Biologics, Cancers, Combination, Disease Indication, Inflammatory Disorders, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Single-chain Knobs-in-holes Bispecific Antibody Construction

Unmet Need: In the United States, 40% of males and 38% of females will develop cancer in their lifetimes. Additionally, as of 2015, the annual direct medical costs of cancer stood at $80.2 billion. Targeted therapies, such as monoclonal antibody drugs, show great promise in cancer treatment, but these therapies still have many important limitations...

Published: 10/24/2025 | Inventor(s): Jamie Spangler, Denis Wirtz, Huilin Yang, Wentao Wang, Michelle Karl

Keywords(s): Antibodies, Discovery/Research Tools, Monoclonal Antibodies, Research Reagent, Therapeutic Matter, Therapeutic Substance Synthesis Method, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies, Technology Classifications > Research Tools > Research Antibodies

Engineered Bispecific Antibodies for Targeted Inhibition of Tumor Metastasis

Description: Unmet Need. In the United States, 40% of males and 38% of females will develop cancer in their lifetimes. Many types of cancers, including triple negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC), have devastatingly low five year survival rates, even after the removal of primary tumors. Poor prognoses for these cancer...

Published: 10/24/2025 | Inventor(s): Jamie Spangler, Denis Wirtz, Huilin Yang, Wentao Wang, Michelle Karl

Keywords(s): Target, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies, Clinical and Disease Specializations > Oncology